Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Rajyalakshmi Luthra, PhD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Gautam Borthakur, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Farhad Ravandi, MBBS, Susan M. O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2727.

https://doi.org/10.1182/blood.V122.21.2727.2727

Published: 2013

Journal Articles

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Mona Lisa Alattar, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Carlos Guillermo Romo, MD, Sara E Dellasala, RN, Sherry Pierce, Srdan Verstovsek, MD, PhD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 2728.

https://doi.org/10.1182/blood.V122.21.2728.2728

Published: 2013

Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4019.

https://doi.org/10.1182/blood.V122.21.4019.4019

Published: 2013

Journal Articles

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

Jan A. Burger, MD, PhD, Michael J. Keating, MD, William G. Wierda, MD, PhD, Julia Hoellenriegel, Ghayathri Jeyakumar, MD, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Susan Lerner, MS, Gracy Zacharian, Xuelin Huang, Hagop M. Kantarjian, MD, Susan O'Brien, MD

Blood (2013) 122 (21): 675.

https://doi.org/10.1182/blood.V122.21.675.675

Published: 2013

Journal Articles

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Preetesh Jain, Hagop Kantarjian, Aziz Nazha, Susan O’Brien, Elias Jabbour, Carlos Guillermo Romo, Sherry Pierce, Marylou Cardenas-Turanzas, Srdan Verstovsek, Gautam Borthakur, Farhad Ravandi, Alfonso Quintás-Cardama, Jorge Cortes

Blood (2013) 121 (24): 4867–4874.

https://doi.org/10.1182/blood-2013-03-490128

Published: 2013

Includes: Supplemental data

Journal Articles

Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients

Hui Yang, MD, PhD., Carlos E. Bueso-Ramos, MD, PhD, Sherry A. Pierce, RN, BS, Yue Wei, PhD, Zhihong Fang, Martin Nguyen, Michael Fernadez, Marylou Cardenas-Turanzas, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3845.

https://doi.org/10.1182/blood.V120.21.3845.3845

Published: 2012

Journal Articles

Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Blood (2012) 120 (21): 2827.

https://doi.org/10.1182/blood.V120.21.2827.2827

Published: 2012

Journal Articles

Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, MD, Ohad Benjamini, MD, Sherry A. Pierce, RN, BS, Marylou Cardenas-Turanzas, Srdan Verstovsek, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 70.

https://doi.org/10.1182/blood.V120.21.70.70

Published: 2012

NARROW

BCR-ABL Fusion Transcripts In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Experience With Ponatinib From MD Anderson Cancer Center

Analysis Of Responses (complete cytogenetic response and major molecular response) Achieved With Different Tyrosine Kinase Inhibitor (TKI) Modalities and Their Impact On Long Term Outcomes In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) – Analysis From a Single Institution

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients

Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only